Gilead Sciences Inc. (GILD) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Gilead Sciences Inc. (GILD)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

91.00

1.06 (1.18%)

At close: Jan 14, 2025, 3:59 PM

90.64

-0.40%

Pre-market Jan 15, 2025, 04:25 AM EST

undefined% (undefined)

Bid	90.16
Market Cap	113.41B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	4.43
PE Ratio (ttm)	20.54
Forward PE	n/a
Analyst	Buy

Ask	91
Volume	4,866,664
Avg. Volume (20D)	6,631,557
Open	90.49
Previous Close	89.94
Day's Range	89.83 - 91.48
52-Week Range	62.07 - 98.90
Beta	undefined

About GILD

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, V...

[Show more]

Industry Drug Manufacturers - General

Sector Healthcare

IPO Date Jan 22, 1992

Employees 18,000

Stock Exchange NASDAQ

Ticker Symbol GILD

Website https://www.gilead.com

Analyst Forecast

According to 24 analyst ratings, the average rating for GILD stock is "Buy." The 12-month stock price forecast is $98.5, which is an increase of 8.24% from the latest price.

Buy 58.33%

Hold 41.67%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Gilead Sciences Inc. is scheduled to release its earnings on Feb 11, 2025, after market closes.
Analysts project revenue of $7.16B, reflecting a 0.63% YoY growth and earnings per share of 1.71, making a -0.58% decrease YoY.

Why Price Moved

2 months ago · Source

-4.03%

Shares of pharmaceutical and healthcare stocks are... Unlock content with Pro Subscription

2 months ago · Source

+6.77%

Gilead Sciences shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 guidance.

News

2 days ago · youtube.com

Final Trade: ANF, GILD

The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.

2 days ago · seekingalpha.com

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil...

1 day ago · seekingalpha.com

Gilead Sciences, Inc. (GILD) JPMorgan Annual Healthcare Conference - (Transcript)

Gilead Sciences, Inc. (NASDAQ:GILD ) JPMorgan Annual Healthcare Conference Call January 13, 2025 2:15 PM ET Company Participants Daniel O'Day - Chairman and Chief Executive Officer Johanna Mercier - C...

1 day ago · youtube.com

Gilead CEO on funding for new HIV prevention medicine

CNBC's Angelica Peebles and Gilead chairman and CEO Daniel O'Day join ‘Squawk Box' to discuss the company's new HIV prevention medicine, impact of the incoming Trump administration on health care, and...

2 days ago · youtube.com

Gilead CEO Daniel O'Day on new HIV prevention medicine: It's going to change the face of HIV

CNBC's Angelica Peebles and Gilead chairman and CEO Daniel O'Day join 'Squawk Box' to discuss the company's new HIV prevention medicine, impact of the incoming Trump administration on health care, and...

2 days ago · https://thefly.com

Compugen initiated with bullish view at Oppenheimer, here's why

Compugen +0.05 (+3.14%) AstraZeneca +0.44 (+0.66%) Gilead +0.7 (+0.79%)

3 days ago · reuters.com

Gilead, LEO Pharma partner to develop programs for inflammatory diseases

Gilead Sciences said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat patients with inflammatory diseases.

3 days ago · businesswire.com

Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases

FOSTER CITY, Calif. & BALLERUP, Denmark--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and commercializatio...

6 days ago · zacks.com

Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know

In the latest trading session, Gilead Sciences (GILD) closed at $89.14, marking a -1.64% move from the previous day.

1 week ago · proactiveinvestors.co.uk

Gilead backs proposed Poolbeg Pharma's proposed tie-up with HOOKIPA

Gilead Sciences Inc (NASDAQ:GILD, ETR:GIS), the largest shareholder in HOOKIPA Pharma, has thrown its backing behind the proposed merger with Poolbeg Pharma PLC (AIM:POLB). Gilead, which holds just un...

1 week ago · zacks.com

Gilead Sciences (GILD) Stock Declines While Market Improves: Some Information for Investors

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $91.41, denoting a -0.51% change from the preceding trading day.

1 week ago · 247wallst.com

Jefferies Top 2025 Stock Picks Include 5 Sizzling Large Cap Dividend Blue Chips

As the calendar turns over to 2025, the leading Wall Street firms are releasing their top stock picks for the new year.

2 weeks ago · seekingalpha.com

Gilead Sciences: 2025 Preview, A Buy Thanks To Thriving HIV Franchise

Gilead's stock is rated a "buy" due to its thriving HIV business, promising oncology pipeline, and potential for long-term growth despite some volatility. The company's Q3 earnings show strong perform...

2 weeks ago · zacks.com

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.

3 weeks ago · schaeffersresearch.com

8 Trading Lessons to Take From Our 2024 Stock Picks

Subscribers to Chart of the Week received this commentary on Sunday, December 8.

3 weeks ago · businesswire.com

Gilead Sciences to Present at Upcoming Investor Conference

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference: J.P. Morgan Healthcare Con...

3 weeks ago · zacks.com

Gilead Stock Gains 15.4% in a Year: Should You Buy, Sell or Hold?

GILD has put up a steady performance in 2024, with a new drug approval, positive data readouts and strong quarterly results. We believe there is more room for growth, given GILD's strong fundamentals.

3 weeks ago · investorplace.com

Cash is Down, Valuations Are Up, but Stay Invested

Bullish sentiment rules

3 weeks ago · zacks.com

GILD's Trodelvy Gets Second Breakthrough Therapy Tag for Lung Cancer

Gilead announces that the FDA grants a second Breakthrough Therapy designation to Trodelvy for the extensive-stage small cell lung cancer indication.

4 weeks ago · zacks.com

5 High Earnings Yield Value Picks to Buy for 2025

Unlock your portfolio value with these high earnings yield value stocks, PBI, GPOR, KINS, NATL and GILD.

Load More News